MacroGenics, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023; balance-sheet comparisons are against December 31, 2022. MacroGenics is a clinical-stage biopharmaceutical company developing antibody-based cancer therapeutics. It also markets MARGENZA with a partner and earns collaboration, manufacturing, and royalty revenue. Three products originating from its pipeline or partnered programs had received FDA approval by the filing date: MARGENZA, TZIELD, and ZYNYZ.
Financial performance and liquidity
| Metric | Q1 2023 | Q1 2022 / prior period |
|---|---|---|
| Total revenue | $24.5 million | $11.1 million |
| Operating loss | $38.4 million | $66.6 million |
| Net loss | $38.0 million; $0.61 per share | $66.4 million; $1.08 per share |
| Research and development | $45.9 million | $61.4 million |
| Selling, general and administrative | $13.5 million | $16.3 million |
| Operating cash flow | $(12.8) million | $(57.7) million |
| Cash and cash equivalents | $224.3 million | $108.9 million at Dec. 31, 2022 |
| Marketable securities | $17.4 million | $45.5 million at Dec. 31, 2022 |
| Total current assets / liabilities | $288.9 million / $45.6 million | $222.2 million / $48.6 million at Dec. 31, 2022 |
Revenue included $16.7 million from collaborative and other agreements, $3.5 million of product sales, $3.6 million of contract manufacturing, $0.4 million of royalty revenue, and $0.3 million from government agreements. The filing does not provide a clear consolidated gross-margin figure. Interest and other income was $1.1 million; interest expense was $0.7 million, primarily non-cash interest on the future-royalty financing.
Cash, cash equivalents, and marketable securities totaled $241.7 million at quarter-end. The company reported no conventional borrowings in the presented balance sheet, but recorded a $100.2 million liability related to its sale of future TZIELD royalties. Total liabilities were $234.2 million and stockholders’ equity was $109.3 million. Financing cash flow of $100.1 million included $99.7 million of net proceeds from the royalty transaction. Investing cash flow was positive $28.1 million, largely reflecting net maturities of marketable securities; cash increased by $115.4 million during the quarter.
Material changes versus Q1 2022
- Revenue increased $13.4 million, or 121%, principally because MacroGenics recognized a $15.0 million Incyte milestone upon FDA approval of ZYNYZ and began recognizing revenue under Incyte’s manufacturing agreement. These gains were partly offset by $5.0 million less revenue under the 2018 Zai Lab agreement.
- R&D expense declined $15.5 million, or 25%, reflecting lower costs for vobramitamab duocarmazine, enoblituzumab, margetuximab, flotetuzumab, and tebotelimab; increased ADC and lorigerlimab spending partly offset the decreases.
- Net loss narrowed by $28.4 million. Operating cash use also fell, with the company citing milestone receipts from Incyte and Provention as benefits to Q1 2023 operating cash flow.
- In March, MacroGenics received $100.0 million upfront from DRI for its single-digit TZIELD royalty interest. It retains other TZIELD milestone interests and a right to share in royalties above a specified annual threshold. The proceeds are accounted for as financing, not revenue.
- Provention owed $30.0 million for an achieved TZIELD milestone at March 31; following Provention’s acquisition by Sanofi in April, Sanofi accelerated and paid the balance after quarter-end.
Outlook, commentary, and risks
- Management said cash, cash equivalents, and marketable securities, together with anticipated and potential collaboration payments, product revenue, and royalties, should fund operations through 2025. The liquidity note separately states that current resources are sufficient for at least twelve months from the filing date. Both assessments depend on forecasts and expected funding sources.
- Spending plans include the Phase 2 TAMARACK study of vobramitamab duocarmazine in metastatic castration-resistant prostate cancer, a planned Phase 2 lorigerlimab study in that disease, and other clinical and preclinical programs. The company expects continued losses and an increasing accumulated deficit.
- No numerical revenue or earnings guidance was provided. Collaboration revenue and milestone timing can vary substantially. Incyte’s retifanlimab approval created potential additional royalties and milestones, but future payments depend on development, regulatory, and commercial outcomes. Gilead’s agreement also includes options and potential milestones and royalties contingent on exercise and successful development and commercialization.
- Key risks include clinical and regulatory uncertainty, the need for additional capital, reliance on collaborations and milestone payments, competition, manufacturing and commercialization execution, and macroeconomic conditions including inflation, higher interest rates, geopolitical uncertainty, and financial-market disruption. If funding or agreements are insufficient, MacroGenics may delay, reduce, or discontinue programs or cut other expenses.
- MacroGenics expanded its Synaffix antibody-drug-conjugate license in March to cover seven targets. If all targets succeed, potential development, regulatory, and sales milestones could total up to $2.8 billion, plus low-single-digit royalties; these are contingent obligations, not current debt.
- The Fourth Circuit affirmed dismissal of a securities class action on March 2, 2023. The company reported no material change to its previously disclosed risk factors and stated that disclosure controls were effective.
Important facts for investors to verify
- Clinical-trial progress, enrollment, data timing, and funding needs for vobramitamab duocarmazine, lorigerlimab, and other pipeline programs.
- Assumptions underlying the stated runway through 2025, including expected collaboration receipts, product revenue, royalties, and R&D spending.
- Incyte’s commercialization of ZYNYZ, future retifanlimab milestones and royalties, and the timing and scope of manufacturing revenue.
- DRI royalty-sale terms, future TZIELD royalty estimates, and the $100.2 million liability’s effective-interest assumptions; repayment estimates use unobservable Level 3 inputs and may change.
- Receipt and timing of remaining contingent milestone payments, including TZIELD-related amounts, and the extent to which option-based collaborations with Gilead and Zai Lab advance.
- Potential dilution and capital needs: MacroGenics sold 95,000 shares through its ATM program for approximately $0.6 million net in the quarter and entered a new ATM agreement with up to $100 million of capacity.